An antiserum raised against a peptide was used to select a unique RNA species from a degenerate pool of RNAs designed to resemble an autoantibody recognition site in U1 RNA. The peptide and the selected RNA epitope could compete for antibody binding, suggesting that both RNA and peptide epitopes occupy the same or overlapping antigencombining sites. Thus, the RNA epitope functioned as a speciffic inhibitor of the antibody-antigen interaction. We demonstrate that the RNA epitope can be used to tag unrelated RNA molecules and also to detect the presence of the antibody. We propose that sequence-specific recognition of RNA by antibodies may involve protein-RNA contacts similar to those occurring in other nucleic acid-binding proteins. In addition, these findings are compatible with the suggestion that nucleic acidbinding autoantibodies may arise through immunological cross-reactivity between proteins and nucleic acids.
Antibodies reactive with nucleic acids are commonly found in the serum of patients with various autoimmune disorders, such as systemic lupus erythematosus (1) . Although the occurrence of antibodies reactive with RNA (2) and doublestranded DNA has been studied in the context of autoimmunity (3) (4) (5) (6) (7) (8) (9) , the origins of these antibodies are poorly understood. Models proposed for the etiology of nucleic acidbinding autoantibodies include polyclonal B-cell activation, antigen-specific stimulation, idiotype network interactions, and cross-reactivity (6, 8, (10) (11) (12) .
Autoantibodies in human sera can bind discrete RNA species within complex mixtures of molecules, implying the recognition of sequence-specific RNA epitopes (4, 6, 13) . For example, sera reactive against portions of U1 RNA and tRNA were shown to select these species out of a pool oftotal HeLa cell RNA in an immunoprecipitation assay (4) . An RNA epitope in U1 RNA was defined by using an anti-Ul RNA antibody to select discrete fragments from a pool of partially digested U1 transcripts; however, such an approach is limited to the use of known RNA ligands (12) .
The experiments described in this paper extend this approach by using a complex mixture of RNA transcripts containing synthetically randomized segments and recovering those subpopulations capable of binding to an antibody. Thus, a pool of degenerate RNA species was produced by in vitro transcription of an oligodeoxyribonucleotide template containing inverted complementary sequences flanking 10 random nucleotides (Fig. 1) . These sequences were chosen to resemble the second stem of U1 RNA, based on the prior demonstration that U1 stem-loop II forms an RNA epitope (6, 12) . Transcripts synthesized from the degenerate oligonucleotide were used in a direct antibody-RNA-binding assay. Molecules that bound the antibody were recovered by standard reverse transcription, PCR amplification, and subcloning. Similar approaches have been used previously to derive RNA ligands for known nucleic acid binding proteins, such as T4 DNA polymerase (14) and Ul-small nuclear ribonucleoprotein (RNP) A protein (15) , as well as RNA molecules that bind specific small dye ligands (16) .
The antibodies used in the RNA-selection procedure were from a rabbit antiserum raised against a synthetic 13-amino acid peptide (designated glO) representing the NH2 terminus of the bacteriophage T7 gene 10 protein. Thus, the anti-glO serum constitutes a general reagent for recognizing glO fusion proteins expressed from pET T7 vectors (17, 19) . While using this serum in RNA-selection experiments, we recovered a specific RNA sequence capable of binding directly to the antiserum. We report that this RNA epitope, designated D10, and the glO peptide can compete with each other for the same antibody-combining site. Furthermore, unrelated RNA molecules tagged by the D10 RNA epitope were recognized by the antiserum. Thus, an anti-peptide serum has been produced that can be used in epitope-tag experiments with either proteins or RNAs.
MATERIALS AND METHODS
Preparation and Characterization of an Antiserum Reactive with the glO Peptide. A 13-amino acid peptide was synthesized representing the NH2 terminus of glO fusion proteins expressed from the Studier T7 expression vectors (17) (peptide sequence: NH2-MASMTGGQQMGRC-COOH amide, purchased from Multiple Peptide Systems, San Diego). The first 11 amino acids represent the gene 10 protein, the arginine is encoded by the linker in these expression vectors, and the cysteine was incorporated for conjugation to the carrier. The peptide was coupled to keyhole limpet hemocyanin (Sigma) with the cross-linker MBS (3-maleimidobenzoyl-N-hydroxysuccinimide ester, Boehringer Mannheim). A high-titer antiserum was obtained from rabbits immunized with the peptide-carrier conjugate. The specificity of the antiserum was characterized by using reported immunoblot and immunoprecipitation methods (18, 19) , with details as follows. Recombinant proteins were expressed in bacteria by using the Studier T7 system as published (19) . Immunoblots were probed with various sera diluted 1:2000 and decorated with 1251-labeled protein A. 35S-labeled proteins were prepared by in vitro transcription of cDNA constructs with T7 RNA polymerase followed by translation in rabbit reticulocyte lysates.
Selection of Specifically Bound RNA by Immunoprecipitation. RNA was prepared by in vitro transcription of PCRgenerated templates as described (15 Antibc 0.2% vanadyl ribonucleoside complexes/tRNA at 50 Iug/ml/ bovine serum albumin at 50 gg/ml) (20) . RNA was added, and the reactions were incubated at 370C for 7 min. The pellets were washed five times with NT2 buffer. Higher stringency washes included 0.5 M urea in the first wash. RNA was recovered by phenol extraction and ethanol precipitation. RNAs were reverse transcribed, and cDNAs were subjected to PCR amplification as described (15) . The amplified template was used to repeat the above cycle for two additional rounds. The final PCR product was digested with BamHI, cloned, and sequenced.
Competition Experiments. Competition experiments were done by adding the various competitors to 32P-labeled RNA or 35S-labeled in vitro-translated glO-small nuclear RNP-A fusion protein before immunoprecipitation. Bound RNAs were analyzed on 6% denaturing acrylamide gels, and proteins were analyzed on SDS/10%o PAGE gels, followed by autoradiography.
Immunoprecipitation in HeLa Ceil Extracts. 32P-labeled HeLa cell extracts and 32P-labeled deproteinized HeLa cell RNA were prepared as reported (19) . 32P-labeled in vitro transcripts were mixed with either HeLa cell extract or HeLa cell RNA under the D10 binding conditions described above. The anti-RNA reactivities in the anti-glO serum and in the anti-Ul RNA patient serum (EW) were normalized by using RESULTS glO Antiserum Recognizes a Specific Peptide Epitope. A high-titer rabbit antiserum, termed anti-glO, was prepared against the T7 bacteriophage glO peptide. Fig. 2 shows that the serum was specific for proteins containing the glO fusion peptide as assayed by immunoblot and immunoprecipitation. A more demanding test of an epitope tag is recognition of the tagged molecule within the context of a macromolecular complex. Among the potential complications of using an epitope tag are its interference in assembly of a complex or its inaccessibility within an assembled complex. Previous studies have used the glO tag to immunoprecipitate RNP complexes formed in vitro between glO-U1-A and U1 RNA (15, 19, 21) . Other RNP complexes analyzed by using the glO epitope include those formed by U1-70K (J. Romac, D. Graff, and J.D.K., unpublished work), U2-B" (19) , U2-A' (19) , and 60-kDa Ro-RNP (S. Deutscher (Fig. 1) . These RNAs were transcribed from -1 x 1011 molecules of degenerate oligodeoxynucleotide template (15) . Assuming that most templates are transcribed at least once, all possible RNA species should be redundantly represented. After three cycles of antibody selection (described in ref. 15 and Methods and Materials) with high-stringency washing, a single RNA species, D10, was obtained in 45 out of 45 isolates. Low-stringency selection, without the use of urea in the wash step, yielded five different, but related, species (data not shown) (Fig. 1) .
To rule out the possibility of nonspecific RNA binding, 32P-labeled D10-RNA precipitations were done with either Biochemistry: Tsai et protein A-Sepharose beads alone, preimmune serum, or anti-glO serum. The D10 RNA bound only to the anti-glO serum (Fig. 3, lane 1) , confirming that binding is specific for the postimmune antiserum. Immunoprecipitation experiments with various RNA species suggest that the anti-glO serum is specific for the D10 RNA sequence. For example, an unrelated RNA was not recognized (Fig. 3, lane 6 RNA bound to any surface of any antibody molecule in the serum. Because the preimmune serum showed no reactivity toward the D10 RNA, the most likely RNA-binding surface is the antigen-combining site of the g1O-specific antibodies. This possibility was tested by competition experiments with the glO peptide and the D10 RNA. Antibody-RNA complexes were formed in the presence ofcompetitor glO peptide or control peptide (Fig. 4A) or with increased amounts of glO peptide (Fig. 4B) , and uncompeted RNA was recovered by immunoprecipitation. As expected, neither bovine serum albumin nor an unrelated peptide showed any effect on D10-RNA precipitation by the anti-glO serum (Fig. 4A, lanes  4 and 5) . However, increased amounts of glO peptide inhibited RNA binding by the antiserum (Fig. 4B, lanes 1-6) .
Similarly, the D10 RNA was examined for its ability to inhibit complex formation between a glO fusion protein and the glO-reactive antibodies. The D10 RNA could compete with the glO fusion protein for binding to the antibody (Fig.  4C, lane 4 ). An unrelated RNA could not compete for the antibody-combining site (Fig. 4C, lane 5) . In addition, increased amounts of D10 RNA were able to progressively compete with an 35S-labeled glO fusion protein (Fig. 4D, lanes  1-6) . These results are consistent with competition between two antigens for the same or overlapping antigen-binding sites on the antibody. The finding that essentially all of the reactive antibodies recognized both the RNA and peptide epitopes implies that the immune response was mounted against a single epitope on the glO peptide and that the D10 RNA contains a single cross-reactive epitope.
Use of the D10 RNA as an Epitope Tag. To test whether D10 can serve as an epitope tag for RNA, the D10 DNA sequence (Fig. 1) was cloned into pGEM-3zf(+), and various length transcription templates were produced by truncation 3' to the D10 epitope. RNA was synthesized in vitro from these templates, and the anti-glO serum was used to immunoprecipitate the D10-tagged pGEM-3zf(+) RNAs. All fusion RNAs were precipitated by the anti-glO serum (Fig. SA, lanes  2-5) , whereas a control RNA was not precipitated (lane 1). Therefore, the D10 sequence is functional as an RNA epitope tag in these contexts.
The complexity of RNA sequences within the pool of artificially randomized 10-mer loops (15) anti-glO serum in the presence of total HeLa cell RNA (Fig.  SB, lanes 9-11) and extract (lane 14). In contrast, transcripts of exogenous NEUl RNA (see legend to Fig . 5B) were not immunoprecipitated by the anti-glO serum (Fig. 5B, lanes 8  and 13) ; however, they were recognized by a patient serum, EW, that binds the second stem-loop of U1 RNA (12) (lane 5). Furthermore, the anti-glO serum was not reactive with HeLa cell RNA (Fig. 5B, lane 7) . These results show that the D10 epitope can be recognized in the presence oftotal cellular RNA and proteins. Furthermore, the fact that the U1-3Dx construct was recognized by the anti-glO serum identifies a minimal sequence required for antibody recognition as CCUGGUGGAGCAGG, in the context of a stem. DISCUSSION A polyclonal antiserum raised against a 13-amino acid peptide (glO), derived from the bacteriophage T7 gene 10 protein, was used in an in vitro RNA selection procedure to isolate a specific RNA epitope, designated D10. The initial pool of RNA that was presented to the anti-glO serum contained the sequence of the second stem of U1 RNA, with a 10-nucleotide degenerate loop sequence. This particular structure was used for two reasons: (i) the second stem-loop of U1 RNA forms a naturally occurring RNA epitope recognized by autoantibodies from many systemic lupus erythematosus patients (6, 12) ; (ii) a stem context provides some stability to the RNA epitope independently of sequences surrounding the epitope. Thus, we have constructed a library of distinctive potential RNA epitopes containing variable loops flanked by constant stems.
To select the D10 epitope, this library of RNAs was incubated with the anti-glO serum in a standard RNA immunoprecipitation assay. After three cycles of selection at high stringency, the PCR-amplified products yielded a single specific loop sequence, 5'-UGGUGGAGCA-3', in each of 45 isolates. This loop sequence, when placed in the context of the third stem-loop of U1 RNA, was also recognized by the anti-glO serum. Thus, the loop constitutes a minimal epitope. The D10 epitope could form within the context of a variety of unrelated RNA sequences to which it was tagged; thus, its folding appears relatively insensitive to external structural influences. It is noteworthy that the predicted folded structure of the RNA epitope contained a 6-nucleotide loop with an extended stem compared to that of U1 RNA (Fig. 1) .
Although antibodies are not usually considered to be sequence-specific nucleic acid-binding proteins, they may share structural characteristics with some nucleic acidbinding proteins. For example, a high incidence of aromatic residues and arginines has been found in the complementarity-determining regions of antibodies (22) . Aromatic residues are known also to play a central role in several classes of nucleic acid-binding proteins, including the single-strand DNA-binding proteins, such as gene 5 protein (23) , and the RNA-recognition motif family of RNA-binding proteins (24) . A model of antigenic recognition by antibodies has been offered (22) that parallels the one proposed for RNA recognition by the RNA-recognition motiffamily (24) . Both models suggest that aromatic amino acids and arginines determine approximate fit of the ligand (epitope), whereas variable residues determine the specificity and affinity of binding. Thus, both binding mechanisms may reflect a common evolutionarily successful mode of molecular recognition.
The fact that a majority of the glO antibodies can crossreact with the glO peptide and the D10 RNA raises the question of whether these epitopes have similar tertiary (Fig. 1) was cloned into the BamHI site of PGEM-3zf(+) to produce tagged-vector RNA, and transcripts with different 3' termini were generated with SP6 RNA polymerase. The anti-glO serum was used to precipitate the following transcripts. Lanes: 1, Ul RNA (negative control); 2, D10 RNA; 3-5, increased lengths of D10-tagged vector RNA; 6-10, supernatants from lanes 1-5, respectively. Approximate nucleotide sizes are indicated by arrowheads. (B) U1 RNA was tagged with the D10 epitope by replacing loop III, sequence CAAAUGU, with the sequence UGGUGGAGCA (construct U1-3Dx). Lanes: 1, total deproteinized HeLa cell RNA; 2, total HeLa cell RNA mixed with exogenous NEU1 transcript (wild-type U1 RNA sequence plus extra 3' nucleotides from the U1 gene); 3, total HeLa cell RNA mixed with exogenous U1-3Dx plus extra 3' nucleotides; 4-6, RNA mixtures from lanes 1-3 precipitated with an anti-Ul RNA serum (EW); 7-9, RNA mixtures from lanes 1-3 precipitated with the anti-glO serum; 10 and 11, same as lane 9, but U1-3Dx was diluted 1:3 and 1:9, respectively; 12-14, RNA mixtures from lanes 1-3, except that total HeLa cell extract was used instead of HeLa cell RNA and precipitated with anti-glO serum; 15-17, RNA mixtures from lanes 1-3 precipitated with preimmune (PI) serum. Only 0.5% of the total RNA mixtures was loaded in lanes 1-3, and these lanes were exposed three times longer than the other lanes. U1-3Dx consistently produced a doublet, as seen in lanes 3, 6, 9-11, and 14. For unexplained reasons, a small amount of endogenous Ul RNA was detected with total HeLa cell extract (lanes 12-14) . 5S, 5S ribosomal RNA.
structures. Although polynucleotides and polypeptides favor different patterns of folding, and hence, different tertiary structures, it is possible that the RNA and peptide epitopes could duplicate some of the key contacts with the glO antibody. Alternatively, even dissimilar epitopes could be accommodated by the same antibody due to torsional flexibility of aromatic residues typically found in antigencombining sites (22) .
We have shown that the D10 RNA can be used as an RNA epitope tag, much like the glO peptide has been used to tag proteins. This approach allows the use of antibodies to isolate or detect tagged RNA complexes. Unlike other RNA tags, such as biotin, it may be possible to express D10-fusion RNAs in transfected cells or transgenic animals. Furthermore, the ability to create RNA epitopes reactive with specific antibodies provides a means of analyzing patient sera. For example, it may be possible to use RNA epitopes for detection of disease-specific antibodies or as inhibitors of a disease-related antigen-antibody interaction.
Antibodies that bind RNA have been found in the sera of patients with various autoimmune diseases. The finding that an antibody formed against a peptide can also bind strongly to an RNA molecule suggests that a cross-reactive mechanism may operate in either the origin or continued production of anti-RNA antibodies. This model may apply to anti-DNA antibodies as well. Whether cross-reactivity between a protein and an RNA can occur in a natural state, such as autoimmunity, remains to be demonstrated. Furthermore, it will be interesting to determine whether any human pathogens can elicit the production of anti-protein antibodies capable of cross-reacting with RNA.
